A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma
Status:
Recruiting
Trial end date:
2025-05-02
Target enrollment:
Participant gender:
Summary
The primary purpose of this study is to identify the recommended phase 2 dose (RP2D[s]) and
schedule(s) to be safe for JNJ-79635322 in Part 1 (dose escalation), and to characterize the
safety and tolerability of JNJ-79635322 at the RP2D(s) in Part 2 (dose expansion).